Onco-Innovations (CSE:ONCO; FRANKFURT:W1H; WKN:A3EKSZ) has announced that its exclusively-licensed, patented polynucleotide kinase 3’-phosphates (PNKP) inhibitors technology holds the potential to significantly enhance the effectiveness of various cancer treatment options across a wide range of cancer types, including colorectal, breast, and lung cancer.
The company explains that PNKP inhibitors technology targets cancer cells to effectively eliminate them, showing promise as both a standalone therapy and in combination with radiation and chemotherapy.
In a statement, Thomas O’Shaughnessy, CEO of Onco-Innovations, said, “We believe our innovative technology could be a game-changer in oncology, offering new hope to millions of patients worldwide where traditional therapies have struggled.”
“This technology not only has the potential to transform cancer treatment but, upon successful completion of U.S. FDA Phase 1 – 3 clinical trials, also positions our company to tap into the multi-million-dollar oncology market. With the company expected to commence Phase 1 clinical trials this year, we are excited about the transformative potential Onco-Innovations could have as we strive to transform cancer treatment worldwide,” Mr. O’Shaughnessy added.
